ストックスクリーナーアプリを入手
19.03
4.62%
0.84
アフターアワーズ：
19.29
0.26
+1.37%
前日終値:
$18.19
開ける：
$18.52
24時間の取引高:
2.56M
Relative Volume:
1.20
時価総額：
$14.03B
収益：
$956.00K
当期純損益:
$-196.68M
株価収益率:
-79.29
EPS:
-0.24
ネットキャッシュフロー:
$-113.02M
1週間 パフォーマンス:
+6.61%
1か月 パフォーマンス:
+2.48%
6か月 パフォーマンス:
+104.40%
1年 パフォーマンス:
+468.06%
1日の値動き範囲:
$18.33
$19.39
1週間の範囲:
$16.46
$19.39
52週間の値動き範囲:
$2.10
$33.89
Summit Therapeutics Inc Stock (SMMT) Company Profile
SMMT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
19.03 | 14.03B | 956.00K | -196.68M | -113.02M | -0.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-08 | 開始されました | Truist | Buy |
| 2024-12-11 | 開始されました | Wells Fargo | Overweight |
| 2024-12-06 | 開始されました | Jefferies | Buy |
| 2024-11-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-09-27 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-08-12 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-07 | 開始されました | Citigroup | Buy |
| 2024-03-26 | 開始されました | Stifel | Buy |
| 2018-06-28 | ダウングレード | Janney | Buy → Neutral |
| 2018-05-02 | 開始されました | Janney | Buy |
| 2018-04-12 | 繰り返されました | Needham | Buy |
| 2018-02-13 | 開始されました | BTIG Research | Buy |
| 2018-01-04 | 開始されました | SunTrust | Buy |
| 2017-12-01 | 再開されました | H.C. Wainwright | Buy |
| 2016-11-16 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2016-10-05 | 繰り返されました | Needham | Buy |
| 2016-09-16 | 開始されました | H.C. Wainwright | Buy |
| 2015-03-30 | 開始されました | Needham | Buy |
| 2015-03-30 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Summit Therapeutics Inc (SMMT) 最新ニュース
Long Term Trading Analysis for (SMMT) - Stock Traders Daily
Is Summit Therapeutics (SMMT) the Best Russell 2000 Stock to Invest in According to Analysts? - MSN
Summit Therapeutics (SMMT) Stock Price, News & Analysis - MarketBeat
Summit Therapeutics (NASDAQ:SMMT) Trading 6.5% HigherWhat's Next? - MarketBeat
Summit Therapeutics: Data Signals A Potential Paradigm Shift In NSCLC (Rating Upgrade) - Seeking Alpha
Summit Therapeutics (NASDAQ:SMMT) Trading Down 6.3%Here's What Happened - MarketBeat
Looking At Summit Therapeutics's Recent Unusual Options Activity - Benzinga
24,879 Shares in Summit Therapeutics Inc. (NASDAQ:SMMT) Bought by SeaCrest Wealth Management LLC - MarketBeat
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Summit Therapeutics (SMMT) Stock Surge Driven by Promising Drug Trials - GuruFocus.com
Why Summit Therapeutics Rocketed 584% in 2024 - MSN
Summit Therapeutics Highlights Success at Healthcare Conference - TipRanks
Summit Therapeutics (NASDAQ:SMMT) Stock Quotes, Forecast and News Summary - Benzinga
(SMMT) Technical Data - Stock Traders Daily
Summit Therapeutics (NASDAQ:SMMT) Shares Up 3.3%Should You Buy? - MarketBeat
Merck rival Summit draws new buy from Truist on deal prospects - Seeking Alpha
Summit Therapeutics (NASDAQ:SMMT) Now Covered by Analysts at Truist Financial - MarketBeat
Truist Securities Initiates Coverage of Summit Therapeutics (SMMT) with Buy Recommendation - MSN
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside - Benzinga
Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
SA Asks: Which biotechs are most likely to be acquired near-term? - Seeking Alpha
The Play On Summit Therapeutics (NASDAQ:SMMT) - Seeking Alpha
Summit Therapeutics Inc. (NASDAQ:SMMT) Receives $33.33 Consensus PT from Analysts - MarketBeat
Prediction: These 3 Healthcare Stocks Will Soar in 2025 - Yahoo Finance
Why Is Summit Therapeutics Inc. (SMMT) Among the Best Multibagger Stocks to Buy Right Now? - Insider Monkey
12 Best Multibagger Stocks to Buy Right Now - Insider Monkey
Insider Stock Buying Reaches US$78.8m On Summit Therapeutics - Simply Wall St
3 Stocks That Could Be Monster Winners in 2025 - Yahoo Finance
Here are Morgan Stanley’s key oncology catalysts for 2025 - Seeking Alpha
Summit Therapeutics (NASDAQ:SMMT) Trading Down 6.2%Here's Why - MarketBeat
103,276 Shares in Summit Therapeutics Inc. (NASDAQ:SMMT) Bought by Franklin Resources Inc. - MarketBeat
10 Best Performing Biotech Stocks in 2024 - Insider Monkey
Is Summit Therapeutics Inc. (SMMT) the Best Performing Biotech Stock in 2024? - Insider Monkey
Geode Capital Management LLC Increases Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Barclays PLC Sells 137,195 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Why Did Summit Therapeutics Inc. (SMMT) Jump Yesterday? - MSN
Why These 10 Stocks Jumped Yesterday - Insider Monkey
Where Will Summit Therapeutics Be in 5 Years? - Yahoo Finance
3 Stocks That Could Turn $1,000 into $5,000 by 2030 - The Motley Fool
Wellington Management Group LLP Sells 223,964 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Summit Therapeutics (NASDAQ:SMMT) Trading Up 6.8%Should You Buy? - MarketBeat
(SMMT) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Has Summit Therapeutics Stock Already Peaked? - AOL
State Street Corp Sells 654,623 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Here's Why Summit Therapeutics Stock Price Rose 6% on Friday - MSN
2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street - Yahoo! Voices
Virtu Financial LLC Makes New Investment in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Wells Fargo Initiates Coverage of Summit Therapeutics (SMMT) with Overweight Recommendation - MSN
Summit Therapeutics Inc (SMMT) 財務データ
収益
当期純利益
現金流量
EPS
Summit Therapeutics Inc (SMMT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Zanganeh Mahkam | Chief Executive Officer |
Mar 26 '24 |
Buy |
3.75 |
30,000 |
112,500 |
30,000 |
| Zanganeh Mahkam | Chief Executive Officer |
Mar 27 '24 |
Buy |
3.72 |
26,000 |
96,720 |
520,814 |
| Dhingra Ankur | Chief Financial Officer |
Mar 26 '24 |
Buy |
3.75 |
100,000 |
375,000 |
354,958 |
0.75%
2.31%
大文字化:
|
ボリューム (24 時間):